UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 14, 2015
International Stem Cell Corporation
(Exact name of registrant as specified in its charter)
Commission File Number: 000-51891
| | |
| Delaware | | 20-4494098 |
(State or other jurisdiction of incorporation) | | (IRS Employer Identification No.) |
5950 Priestly Drive, Carlsbad, CA 92008
(Address of principal executive offices, including zip code)
(760) 940-6383
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 14, 2015, International Stem Cell Corporation (the “Company”) announced that the Therapeutic Goods Administration (TGA) of Australia had cleared a regulatory submission from CytoTherapeutics, the Company’s wholly owned subsidiary, to initiate a Phase I/IIa clinical trial, dose escalation trial using human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson’s disease.
A copy of a press release announcing the clearance of the regulatory submission for the Phase I/IIa clinical trial is attached as Exhibit 99.1 to this Report.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| | |
Exhibit Number | | Description |
| |
| 99.1 | | Press Release, dated December 14, 2015. |
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | INTERNATIONAL STEM CELL CORPORATION |
| | | |
| Date: December 14, 2015 | | | | By: | | /s/ Mahnaz Ebrahimi |
| | | | | | Mahnaz Ebrahimi Chief Financial Officer |
